Spero Therapeutics (SPRO) EPS (Basic) Growth (1y) (2017 - 2026)
Spero Therapeutics (SPRO) EPS (Basic) Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | -16.29% |
| 10 | Spero Therapeutics | 71.31 Mn | 20.53 Mn | - | -441.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.27% |
| Mar 31, 2026 | 48.52% |
| Dec 31, 2025 | 119.82% |
| Sep 30, 2025 | -61.17% |
| Jun 30, 2025 | -480.46% |
| Mar 31, 2025 | -5.85% |
| Dec 31, 2024 | -133.59% |
| Sep 30, 2024 | -404.18% |
| Jun 30, 2024 | -46.15% |
| Mar 31, 2024 | 6.32% |
| Dec 31, 2023 | 54.01% |
| Sep 30, 2023 | 81.62% |
| Jun 30, 2023 | 71.35% |
| Mar 31, 2023 | 75.84% |
| Dec 31, 2022 | 41.57% |
| Sep 30, 2022 | 80.98% |
| Jun 30, 2022 | 35.09% |
| Mar 31, 2022 | 23.37% |
| Dec 31, 2021 | -401.95% |
| Sep 30, 2021 | -29.61% |